Plain language summary of the FOENIX-CCA2 study: Futibatinib for advanced bile duct cancer
This Plain Language Summary of publication article (PLSP) from Future Oncology covers the phase 2 FOENIX-CCA2 study, which tested futibatinib in patients with advanced intrahepatic cholangiocarcinoma (iCCA) with FGFR2 gene alterations. The study aimed to evaluate if futibatinib could shrink tumors, slow cancer growth, and extend survival in patients who had progressed after chemotherapy.
Visit the site using this link to read the article.
This PLSP is based on an article called ‘Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma’ and was published in The New England Journal of Medicine.
Visit The New England Journal of Medicine using the link to read the original article.